Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 7/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.36 |
| ▸ | USP7 | Q93009 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 5/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30325937 | 0.82 | PIK3CD (0.34) | PIK3CDRIPK1EGLN1TTKABL1 | |
| SCHEMBL29265920 | 0.70 | MAP4K4 (0.39) | PIK3CDRIPK1ABL1CSNK2A2CSNK2A1 | |
| SCHEMBL30325877 | 0.69 | CSNK2A2 (0.42) | RIPK1CSNK2A2CSNK2A1 | |
| SCHEMBL29265794 | 0.68 | AURKA (0.42) | ABL1 | |
| SCHEMBL31213973 | 0.65 | RPS6KB1 (0.31) | ABL1KIT | |
| SCHEMBL29265935 | 0.64 | CSNK2A2 (0.40) | PIK3CDRIPK1CSNK2A2CSNK2A1 | |
| SCHEMBL30326340 | 0.64 | BTK (0.41) | RIPK1ABL1CSNK2A2CSNK2A1 | |
| SCHEMBL28197914 | 0.63 | EZH2 (0.57) | — | |
| SCHEMBL22676715 | 0.61 | AURKA (0.47) | PIK3CDTTKUSP7CSNK2A2CSNK2A1 | |
| SCHEMBL21671910 | 0.61 | TSHR (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383905-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2024-11-21 | — | — | US | disclosed |
| EP-4405358-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H Pharmaceuticals Co., Ltd. (CN) | 2024-07-31 | — | — | EP | disclosed |
| CN-118043327-A | FGFR inhibitors and methods of use thereof | 思康睿奇(上海)药业有限公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2023046117-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2023-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383905-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR1, FGFR3, FGFR4 | PIK3CD 889/4885RIPK1 2213/4885EGLN1 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.